The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
5,852
Sort by:
2014 Analysis of the European Therapeutic Drug Monitoring (TDM) Market : Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
This new 291-page report from Venture Planning Group provides a comprehensive analysis of the European therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...
November 2013
291 pages
US Lung Cancer Drug Pipeline Analysis
US$ 1,800.00
... annual statistics published, an estimated 201,144 people in the United States were diagnosed with lung cancer. This figure included 107,164 men and ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Lung Cancer Drug Pipeline Analysis ...
November 2013
385 pages
US Colorectal Cancer Drug Pipeline Analysis
US$ 1,500.00
... that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions ... market based upon development process. Following parameters for each drug profile in development phase are covered in “US Colorectal Cancer Drug Pipeline ...
November 2013
242 pages
US Parkinson's Disease Drug Pipeline Analysis
US$ 1,500.00
... in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Parkinson’s Disease Drug Pipeline Analysis ...
November 2013
241 pages
Global RNAi Drug Pipeline Analysis
US$ 1,500.00
... location. “Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. ... Drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Global RNAi Drug Pipeline ...
October 2013
250 pages
US Orphan Drug Pipeline Analysis
US$ 1,800.00
... from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the ... increasing, thus increasing the profit margins in the future. “US Orphan Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...
October 2013
880 pages
Global Infertility Drug Pipeline Analysis
US$ 1,000.00
... drugs and treatment. The most lucrative markets for infertility drugs are the emerging nations such as India, Brazil, China and Mexico, ... pool of people being affected by lifestyle diseases, thus leading to infertility. “Global Infertility Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
October 2013
60 pages
Orphan Drugs for Cancer Pipeline Analysis
US$ 1,800.00
... patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group ... drug profile in development phase are covered in “Orphan Drugs for Cancer Pipeline Analysis” research report: Drug Profile Overview Alternate Names for Drug ...
October 2013
855 pages
Global HIV Infection Drug Pipeline Analysis
US$ 1,500.00
... to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process. Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Drug Pipeline Analysis” research report: Drug ...
October 2013
300 pages
US Alzheimer Drug Pipeline Analysis
US$ 2,000.00
... observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimer’s disease. Amongst the population in the 80+ age group, almost ... market based upon development process. Following parameters for each drug profile in development phase are covered in “US Alzheimer Drug Pipeline Analysis” ...
October 2013
348 pages
US Prostate Cancer Drug Pipeline Analysis
US$ 1,800.00
... Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes US Prostate Cancer Drug Pipeline by Clinical Phase: Research: 11 Preclinical: 44 Unknown Phase: 4 Phase 0: 1 Phase-I: 22 Phase-I/II: 18 Phase-II: 53 Phase-II/III: 1 Phase-III:14 Marketed: 13
October 2013
375 pages
US Breast Cancer Drug Pipeline Analysis
US$ 1,800.00
... and new therapies would account for more than 25% of the overall market for breast cancer drug treatments. “US Breast Cancer Drug Pipeline Analysis” by ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Breast Cancer Drug Pipeline ...
October 2013
480 pages
Europe Breast Cancer Drug Pipeline Analysis
US$ 1,800.00
... opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Breast Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names ...
October 2013
380 pages
Gene Therapy Drug Pipeline Analysis
US$ 1,500.00
... in development phase enables the reader to identify and understand the Gene Therapy associated with the various diseases. This report enables pharmaceutical ... parameters for each drug profile in development phase are covered in “Gene Therapy Drug Pipeline Analysis” research report: Drug Profile Overview ...
September 2013
185 pages
Malaria Disease Drug Pipeline Analysis
US$ 1,200.00
... purchasing Hard Copy License depending on the location. “Malaria Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated ...
August 2013
185 pages
2013 Drugs of Abuse Testing in France: Hospitals and Commercial Labs
US$ 1,960.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in France: Hospitals and Commercial Labs” is a unique study designed ...
June 2013
260 pages
2013 Drugs of Abuse Testing in Germany: Hospitals, Commercial Labs, Physician Offices
US$ 1,960.00
... of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Germany: Hospitals, Commercial Labs, Physician Offices” is a unique study designed to help current suppliers and potential market entrants ...
June 2013
262 pages
2013 Drugs of Abuse Testing in Italy: Hospitals and Commercial Labs
US$ 1,960.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Italy: Hospitals and Commercial Labs” is a unique study designed ...
June 2013
260 pages
2013 Drugs of Abuse Testing in Japan: Hospitals and Commercial Labs
US$ 2,200.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Japan: Hospitals and Commercial Labs” is a unique study designed ...
June 2013
260 pages
2013 Drugs of Abuse Testing in Spain: Hospitals, Commercial Labs, Ambulatory Care Centers
US$ 1,960.00
... of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Spain: Hospitals, Commercial Labs, Ambulatory Care Centers” is a unique study designed to help current suppliers and potential market entrants ...
June 2013
260 pages
2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs
US$ 1,960.00
... resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ... , such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs” is a unique study ...
June 2013
260 pages
2013 Drugs of Abuse Testing in the US: Hospitals, Commercial Labs, Physician Offices
US$ 2,800.00
... for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in the US: Hospitals, Commercial Labs, Physician Offices” is a unique study designed to help current suppliers and potential market ...
June 2013
262 pages
2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
... a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers” is a unique study designed to help current suppliers ...
June 2013
300 pages
2013 Therapeutic Drug Monitoring (TDM) Market in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
... Acid and Vancomycin. During the next five years, the TDM market will undergo significant transformation. These changes will be caused ... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in the US: Hospitals, Commercial Labs, Physician Offices, ...
June 2013
291 pages
2013 Therapeutic Drug Monitoring (TDM) Market in France: Hospitals and Commercial Labs
US$ 1,960.00
... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in France: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...
June 2013
247 pages
2013 Therapeutic Drug Monitoring (TDM) Market in Italy: Hospitals and Commercial Labs
US$ 1,960.00
... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in Italy: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...
June 2013
247 pages
2013 Therapeutic Drug Monitoring (TDM) Market in Japan: Hospitals and Commercial Labs
US$ 2,200.00
... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in Japan: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...
June 2013
247 pages
2013 Therapeutic Drug Monitoring (TDM) Market in the UK: Hospitals and Commercial Labs
US$ 1,960.00
... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in the UK: Hospitals and Commercial Labs” is a unique ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors ...
June 2013
247 pages
Research Report on China's OTC Drug Market, 2013-2017
US$ 2,400.00
... brand images. Compared with that of countries with advanced medicine levels, China OTC drug industry is featured by late start, fast growth and ... or occupy market by regional advantages. With the standardizing development of domestic OTC drug market and the increase in residents' healthcare consciousness, the ...
May 2013
30 pages
2013 Drugs of Abuse Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan
US$ 6,800.00
... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... , such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan” ...
May 2013
318 pages
2013 Therapeutic Drug Monitoring (TDM) Market: US, Europe (France, Germany, Italy, Spain, UK), Japan
US$ 6,800.00
... shares) $5,500. This new 313-page report from Venture Planning Group contains 83 tables and provides analysis of the global therapeutic ... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market: US, Europe (France, Germany, Italy, Spain, UK), Japan” ...
May 2013
313 pages
CompetitiveWatch Nucleic Acid Testing: Strategic Profiles of Leading Suppliers
US$ 2,800.00
... as extensive listings of companies developing and marketing innovative technologies and products. This report also presents strategic assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios, marketing tactics, technological know-how, new ...
May 2013
549 pages
Drugs of Abuse: A Analysis of the Point-of-Care Testing Market: US, Germany, Spain, Physician Offices, Emergency Rooms, Ambulatory Care Centers
US$ 3,080.00
... their dynamics, trends, structure, size, growth and major suppliers. Five-year test volume and reagent sales forecasts for drugs of ... Offices/Group Practices Emergency Rooms Ambulatory Care Centers Analysis of drugs of abuse procedures Competitive Assessments Assessments of major POC suppliers and ...
April 2013
194 pages
China Vitamin Industry Report, 2012-2015
US$ 1,800.00
... impact of the economic downturn in Europe and the United States, China’s future vitamin market will face grim situation, especially exports even ... also with average export prices lifted to varying degrees . China Vitamin Industry Report, 2012-2015 of ResearchInChina mainly covers the followings: International ...
April 2013
73 pages
Competitor Analysis: Antibody-Drug Conjugates (ADC)
US$ 785.00
Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the ...
April 2013
104 pages
Competitor Analysis: Insulin
US$ 590.00
Product description The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and in...
April 2013
89 pages
Competitor Analysis: Interferon
US$ 590.00
Product description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural...
April 2013
89 pages
Global Oncology Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis, March 2013
US$ 2,650.00
... in 2018. Lucintel, a leading global management consulting and market research firm, has analyzed the global oncology drugs industry and presents its findings in Global Oncology Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis. The industry comprises firms primarily engaged in the development, manufacture, and marketing of oncology drugs. Lucintels ...
March 2013
-
Research Report on China’s Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
US$ 1,800.00
Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion ... patent drug manufacturers. Meanwhile, it is also a huge market. Therefore, the prospect of China’s anti-PH drug market is very bright. The annual growth rate ...
February 2013
40 pages
Research Report on China’s Anti-Alzheimer’s Disease (AD) Drug Market, 2013-2017
US$ 2,800.00
... the end of 2011, people aged 60 and above reached 185 million in China, accounting for 13.7% of the population, with an increase of 0.47 percentage point compared ... market development also accelerates. Although the overall market size of China's anti-AD drug market is relatively small, the growth rate is always ...
January 2013
40 pages
